Publicaciones en colaboración con investigadores/as de University of Groningen (9)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2022

  1. Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitis

    Clinical and Translational Discovery, Vol. 2, Núm. 1

  2. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

2020

  1. Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma

    Hepatology Communications, Vol. 4, Núm. 6, pp. 834-851

2018

  1. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis

    Journal of Controlled Release, Vol. 288, pp. 227-238

2017

  1. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

    Journal of the American Medical Directors Association, Vol. 18, Núm. 12, pp. 1097.e11-1097.e24

2005

  1. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial

    Journal of Hepatology, Vol. 43, Núm. 4, pp. 630-636